Education
About Us
Working with TipRanks
Follow Us
RenovoRx (RNXT)
NASDAQ:RNXT
RNXT Stock Chart & Stats
$0.88
-$0.05(-3.65%)
At close: 4:00 PM EST
$0.88
-$0.05(-3.65%)
Day’s Range― - ―
52-Week Range$0.70 - $1.45
Previous CloseN/A
Volume39.72K
Average Volume (3M)288.82K
Market Cap
$32.32M
Enterprise Value$20.73M
Total Cash (Recent Filing)$10.04M
Total Debt (Recent Filing)$236.00K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Apr 01, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding36,649,918
10 Day Avg. Volume236,040
30 Day Avg. Volume288,821
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)6.80
Price to Sales (P/S)708.18
P/FCF Ratio-3.33
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue22.34
Enterprise Value/Gross Profit32.96
Enterprise Value/Ebitda-2.59
Forecast
1Y Price Target
$10.50Price Target Upside1093.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$4.55M
Bulls Say, Bears Say
Bulls Say
Commercial Launch And Revenue PotentialDirect commercialization of the FDA-cleared RenovoCath could produce initial device sales that raise physician awareness and support a path toward profitability as hospital adoption expands.
Phase 3 Trial ProgressAn independent data-monitoring committee's recommendation to continue the Phase 3 TIGeR-PaC trial signals confidence in trial conduct and could validate RenovoGem's potential if later results meet endpoints.
Platform Versatility And Expanded IndicationsThe Trans-Arterial Micro-Perfusion platform and dual-balloon catheter may improve localized drug delivery and reduce systemic side effects, encouraging investigator-led testing across lung, bile duct, glioblastoma, and sarcoma indications.
Bears Say
Cash Runway And Funding RiskOperating cash runway into late 2026 could necessitate additional financing if commercial uptake lags, risking shareholder dilution or increased borrowing costs.
Development And Regulatory RiskRemaining a clinical-stage company carries high development and regulatory risk, and failure to achieve key trial milestones or approvals could materially hurt the stock.
Uneven Early Revenue And Market AdoptionEarly commercial revenue may be modest and uneven while adoption builds, creating short-term uncertainty for investors and pressure on the company’s valuation.
RenovoRx News
RNXT FAQ
What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $0.70 and its highest was $1.45 in the past 12 months.
What is RenovoRx’s market cap?
RenovoRx’s market cap is $32.32M.
When is RenovoRx’s upcoming earnings report date?
RenovoRx’s upcoming earnings report date is Apr 01, 2026 which is in 28 days.
How were RenovoRx’s earnings last quarter?
RenovoRx released its earnings results on Nov 13, 2025. The company reported -$0.08 earnings per share for the quarter, the consensus estimate of -$0.08 by $0.
Is RenovoRx overvalued?
According to Wall Street analysts RenovoRx’s price is currently Undervalued.
Does RenovoRx pay dividends?
RenovoRx does not currently pay dividends.
What is RenovoRx’s EPS estimate?
RenovoRx’s EPS estimate is -0.08.
How many shares outstanding does RenovoRx have?
RenovoRx has 36,649,918 shares outstanding.
What happened to RenovoRx’s price movement after its last earnings report?
RenovoRx reported an EPS of -$0.08 in its last earnings report, expectations of -$0.08. Following the earnings report the stock price went down -22.998%.
Which hedge fund is a major shareholder of RenovoRx?
Currently, no hedge funds are holding shares in RNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (1093.18% Upside)
$10.50 (1093.18% Upside)
Insider Transactions
Bought Shares
Worth $47.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.1%
Last 30 Days ▲ 25.4%
Last 30 Days ▲ 25.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.27%
12-Months-Change
Fundamentals
Return on Equity
-146.61%
Trailing 12-Months
Asset Growth
11.71%
Trailing 12-Months
Company Description
RenovoRx
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RNXT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
RenovoRx's earnings call highlights a strong commercial momentum with the expansion of their TAMP therapy and RenovoCath device, coupled with solid financial health and promising clinical trial progress. Despite being in the early stages of commercialization and facing a long sales cycle, the overall sentiment is positive due to the significant advancements and strategic positioning for future growth.View all RNXT earnings summariesRNXT Stock 12 Month Forecast
Average Price Target
$10.50
▲(1093.18% Upside)
Technical Analysis
Ovid Therapeutics
―
Grace Therapeutics
―
Jasper Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
3.54% Insiders
4.95% Mutual Funds
10.92% Other Institutional Investors
76.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---